Derosa Giuseppe, Romano Davide, Tinelli Carmine, D'Angelo Angela, Maffioli Pamela
Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy; Center for the Study of Endocrine-Metabolic Pathophysiology and Clinical Research, University of Pavia, Pavia, Italy.
Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
Diabetes Res Clin Pract. 2015 May;108(2):329-35. doi: 10.1016/j.diabres.2015.01.037. Epub 2015 Feb 7.
The aim of this study was to evaluate the prevalence of erectile dysfunction (ED) in a sample of type 2 diabetic patients. As secondary endpoint, we evaluated the levels of some adipocytokines in patients with and without ED.
We enrolled 220 males affected by type 2 diabetes mellitus. We administered the IIEF (International Index of Erectile Function), SAS (self-rating anxiety scale) and SDS (self-rating depression scale) questionnaires. We evaluated body mass index, glycemic control, fasting plasma insulin (FPI), homeostasis model assessment of insulin resistance index (HOMA-IR), lipid profile, sexual hormones, adiponectin (ADN), resistin, retinol binding protein-4 (RBP-4), visfatin, vaspin.
52.9% of patients were affected by ED. Patients with a HbA1c <7% (53 mmol/mol) in all measurements in the two previous years had a lower incidence of ED, while the prevalence of ED increased with the increasing of times HbA1c was >7% (53 mmol/mol). Patients with ED had higher levels of triglycerides, and higher levels of FPI, 9.9 μU/ml vs 8.2 μU/ml (p<0.05). Resistin levels were higher in patients with ED compared to those without ED (p<0.05) and free testosterone was lower in patients affected by ED.
Almost half of type 2 diabetic patients attending our clinic were affected by ED and glycemic control seems to play a role in ED pathogenesis.
本研究旨在评估2型糖尿病患者样本中勃起功能障碍（ED）的患病率。作为次要终点，我们评估了有和没有ED的患者中一些脂肪细胞因子的水平。
我们纳入了220名2型糖尿病男性患者。我们发放了国际勃起功能指数（IIEF）、自评焦虑量表（SAS）和自评抑郁量表（SDS）问卷。我们评估了体重指数、血糖控制、空腹血浆胰岛素（FPI）、胰岛素抵抗指数的稳态模型评估（HOMA-IR）、血脂谱、性激素、脂联素（ADN）、抵抗素、视黄醇结合蛋白4（RBP-4）、内脏脂肪素、内脏丝氨酸蛋白酶抑制剂。
52.9%的患者患有ED。在过去两年的所有测量中糖化血红蛋白（HbA1c）<7%（53 mmol/mol）的患者ED发病率较低，而ED的患病率随着HbA1c>7%（53 mmol/mol）次数的增加而增加。患有ED的患者甘油三酯水平较高，FPI水平也较高，分别为9.9 μU/ml和8.2 μU/ml（p<0.05）。与没有ED的患者相比，患有ED的患者抵抗素水平更高（p<0.05），且患有ED的患者游离睾酮水平更低。
在我们诊所就诊的2型糖尿病患者中，几乎一半患有ED，血糖控制似乎在ED发病机制中起作用。
